Genome-Wide Association Study in Obsessive-Compulsive Disorder: Results from the OCGAS by Mattheisen, Manuel et al.
Genome-Wide Association
Study in Obsessive-Compulsive
Disorder: Results from the OCGAS
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Mattheisen, M., J. F. Samuels, Y. Wang, B. D. Greenberg, A. J. Fyer,
J. T. McCracken, D. A. Geller, et al. 2014. “Genome-Wide Association
Study in Obsessive-Compulsive Disorder: Results from the OCGAS.”
Molecular psychiatry 20 (3): 337-344. doi:10.1038/mp.2014.43. http://
dx.doi.org/10.1038/mp.2014.43.
Published Version doi:10.1038/mp.2014.43
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:22856935
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Genome-Wide Association Study in Obsessive-Compulsive 
Disorder: Results from the OCGAS
Manuel Mattheisen, M.D1,2,3,*, Jack F. Samuels, Ph.D.4, Ying Wang, M.S.4, Benjamin D. 
Greenberg, M.D., Ph.D.5, Abby J. Fyer, M.D.6, James T. McCracken, M.D.7, Daniel A. Geller, 
M.D.8, Dennis L. Murphy, M.D.9, James A. Knowles, M.D., Ph.D.10, Marco A. Grados, M.D.4, 
Mark A. Riddle, M.D.4, Steven A. Rasmussen, M.D.5, Nicole C. McLaughlin, Ph.D.5, Erica 
Nurmi, M.D., Ph.D.7, Kathleen D. Askland, M.D.5, Hai-De Qin, Ph.D.11, Bernadette A. Cullen, 
M.D.4, John Piacentini, Ph.D.7, David L. Pauls, Ph.D.8, O. Joseph Bienvenu, M.D., Ph.D.4, S. 
Evelyn Stewart, M.D.8,12, Kung-Yee Liang, Ph.D.13, Fernando S. Goes, M.D.4, Brion Maher, 
Ph.D.13, Ann E. Pulver, Sc.D.4, Yin-Yao Shugart, Ph.D.11, David Valle, M.D.14, Cristoph 
Lange, Ph.D.2,3, and Gerald Nestadt, M.D.4,*
1Department of Biomedicine and Center for Integrated Sequencing (iSEQ), Aarhus University, 
Aarhus, Denmark
2Harvard School of Public Health, Department of Biostatistics, Boston, MA, USA
3Department of Genomic Mathematics, University of Bonn, Bonn, Germany
4Johns Hopkins University School of Medicine, Department of Psychiatry and Behavioral 
Sciences, Baltimore, MD, USA
5Brown Medical School, Department of Psychiatry and Human Behavior, Providence, RI, USA
6College of Physicians and Surgeons at Columbia University, New York State Psychiatric 
Institute, New York, NY, USA
7University of California, Los Angeles School of Medicine, Department of Psychiatry and 
Biobehavioral Sciences, Los Angeles, CA, USA
8Massachusetts General Hospital and Harvard Medical School, Department of Psychiatry, 
Boston, MA, USA
9National Institute of Mental Health, Laboratory of Clinical Science, Bethesda, MD, USA
10Keck School of Medicine at the University of Southern California, Department of Psychiatry and 
Behavioral Sciences, Los Angeles, CA, USA
11National Institute of Mental Health, Unit of Statistical Genomics, Intramural Research Program, 
Division of Intramural Research Program, Bethesda, MD, USA
12University of British Columbia, Department of Psychiatry, Vancouver, BC, Canada
*Corresponding authors: Dr. Gerald Nestadt, Johns Hopkins University, 600 N. Wolfe St. - Meyer 113, Baltimore, Maryland 21287 
(gnestadt@jhmi.edu; phone +1 410 955 4838) and Dr. Manuel Mattheisen, Department of Biomedicine, Aarhus University, Wilhjelm 
Meyers Alle 4, 8000 Aarhus C, Denmark (mm@hum-gen.au.dk; phone +45 87 16 84 97). 
Conflict of interest
The authors declare no conflicts of interest.
HHS Public Access
Author manuscript
Mol Psychiatry. Author manuscript; available in PMC 2015 September 01.
Published in final edited form as:
Mol Psychiatry. 2015 March ; 20(3): 337–344. doi:10.1038/mp.2014.43.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
13Johns Hopkins University Bloomberg School of Public Health, Department of Mental Health, 
Baltimore, MD, USA
14Johns Hopkins University School of Medicine, Institute of Human Genetics, Baltimore, MD, USA
Abstract
Obsessive-compulsive disorder (OCD) is a psychiatric condition characterized by intrusive 
thoughts and urges and repetitive, intentional behaviors that cause significant distress and impair 
functioning. The OCD Collaborative Genetics Association Study (OCGAS) is comprised of 
comprehensively assessed OCD patients, with an early age of OCD onset. After application of a 
stringent quality control protocol, a total of 1 065 families (containing 1 406 patients with OCD), 
combined with population-based samples (resulting in a total sample of 5 061 individuals), were 
studied. An integrative analyses pipeline was utilized, involving association testing at SNP- and 
gene-levels (via a hybrid approach that allowed for combined analyses of the family- and 
population-based data). The smallest P-value was observed for a marker on chromosome 9 (near 
PTPRD, P=4.13×10−7). Pre-synaptic PTPRD promotes the differentiation of glutamatergic 
synapses and interacts with SLITRK3. Together, both proteins selectively regulate the 
development of inhibitory GABAergic synapses. Although no SNPs were identified as associated 
with OCD at genome-wide significance level, follow-up analyses of GWAS signals from a 
previously published OCD study identified significant enrichment (P=0.0176). Secondary 
analyses of high confidence interaction partners of DLGAP1 and GRIK2 (both showing evidence 
for association in our follow-up and the original GWAS study) revealed a trend of association 
(P=0.075) for a set of genes such as NEUROD6, SV2A, GRIA4, SLC1A2, and PTPRD. Analyses at 
the gene-level revealed association of IQCK and C16orf88 (both P<1×10−6, experiment-wide 
significant), as well as OFCC1 (P=6.29×10−5). The suggestive findings in this study await 
replication in larger samples.
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Introduction
Obsessive-compulsive disorder (OCD) is a psychiatric condition characterized by persistent, 
intrusive, senseless thoughts and urges (obsessions) and repetitive, intentional behaviors 
(compulsions). Affected individuals tend to recognize that their thoughts and behaviors are 
excessive and unreasonable, and often struggle to resist them. The lifetime prevalence of 
OCD is estimated to be between 1–3%, based on national and international population-based 
surveys 1, 2. Patients experience a chronic or episodic course with exacerbations that can 
substantially impair social, occupational, and academic functioning; according to the World 
Health Organization, OCD is among the most disabling medical conditions worldwide 3.
Since the early twentieth century, clinicians have suspected that heredity plays an important 
role in OCD susceptibility. Consistent with this, increased OCD prevalence was identified 
among first-degree relatives of case probands (11.7%), compared to relatives of controls 
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(2.7%; the Hopkins OCD family study) 4. In the same study, the prevalence of OCD in 
siblings of early onset probands was 17.9% (λsib =7.8) and thus within the range found in 
other psychiatric disorders for which a heritable component was reported, such as bipolar 
disorder and panic disorder. Family studies of child and adolescent OCD probands report 
prevalence rates of 7% to 15% in first-degree relatives, and 20–30% of these probands had 
one or more first-degree relative with OCD 5. These findings are consistent with previous 
reports of an increased familial loading in probands with early age at onset. In addition, a 
recent population-based study suggested that (while there is no significant effect of a shared 
environment on OCD risk) the contribution of genetic factors to OCD risk is as high as 
50% 6.
Two genetic linkage studies of OCD have found a suggestive linkage peak on chromosomal 
region 9p24 7, 8. The OCD Collaborative Genetics Study (OCGS) also found suggestive 
genetic linkage peaks on chromosomal regions 3q27-28, 6q, 7p, 1q, and 15q, but none were 
genome-wide significant 9.
There have been numerous candidate gene association studies in OCD 10. A positional 
candidate of particular interest is the neuronal and epithelial glutamate transporter gene 
(SLC1A1). It is located in the region of the replicated linkage peak on chromosome 9p24, 
and there is considerable evidence from imaging, animal, and treatment studies that 
abnormal glutamatergic transmission may be involved in the pathophysiology of OCD 11, 12. 
Several studies have reported positive associations of OCD with this gene, but with different 
SNPs in each 13–19. A recent meta-analysis of these studies did not resolve the issue and was 
not able to report experiment-wise significance for SNPs annotated to SLC1A1 20.
A genome-wide association study was recently completed by the International OCD 
Foundation Genetic Collaborative (IOCDF-GC) 21 with a combined study sample from 22 
sites, comprising 1 465 cases and 5 557 ancestry-matched controls, as well as 400 complete 
trios. In case-control analyses, the lowest P-values were found for two SNPs in perfect LD 
(rs11081062 and rs11663827; r2=1, D′=1 in reference samples from the 1000 genomes 
project 22; P=2.49×10−6 and P=3.44×10−6) Both were located on chromosome 18 within the 
discs, large (Drosophila) homolog-associated protein 1 gene (DLGAP1), a member of the 
neuronal postsynaptic density complex. In the trio analysis, a SNP near the BTB (POZ) 
domain containing 3 gene (BTBD3; rs6131295, chromosome 20), exceeded the genome-
wide significance threshold with a P-value=3.84×10−8. However, when trios were meta-
analyzed together with the case-control samples, the P-value for this variant was 3.62×10−5, 
losing genome-wide significance. Although no SNPs were found to be associated with OCD 
at a genome-wide significant level in the combined trio–case–control sample, a significant 
enrichment of methylation QTLs (P<0.001) and frontal lobe expression quantitative trait 
loci (eQTLs) (P=0.001) was observed within the top-ranked SNPs (P<0.01) from the trio–
case–control analysis, potentially pointing to a broad role in gene expression in the brain, 
and possibly in the etiology of OCD.
In this paper, we report the results of the most recent genome-wide association study of 
OCD, the OCD Collaborative Genetics Association Study (OCGAS). Investigators at 8 
research centers in the United States, including Brown University, Columbia University, 
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Johns Hopkins University, Massachusetts General Hospital, Harvard School of Public 
Health, the National Institute of Mental Health, University of California Los Angeles, and 
the University of Southern California, conducted this collaborative study. The aim of the 
study was to identify common variants associated with OCD using an integrative analyses 
pipeline that involved association testing at both SNP and gene levels. The approach 
included OCD-affected patients (in a family-based analytic setting) with an early onset of 
the disorder (eighteen years and younger) who had been comprehensively assessed via an 
identical diagnostic approach at all recruitment centers.
Materials and methods
Sample
A total of 1 065 families were included in this study (comprising 1 406 patients with OCD 
and 2 895 individuals in total); 621 families were recruited and assessed specifically for this 
study at one of the five participating recruitment sites or the National Institute of Mental 
Health; 444 families had previously been evaluated in one of the earlier studies at Hopkins 
University or by one of the collaborating sites. The sample comprised of 460 complete trios 
(including an affected proband and both parents); 155 pedigrees with a proband and an 
unaffected sibling and 450 families with another structure (complex family structure). An 
additional 192 probands without an additional family member present in the study 
(singletons) were included. A breakdown of the families by site is found in Supplementary 
Table S1.
For study inclusion, probands were required to meet DSM-IV criteria for OCD 23 with onset 
of obsessions and/or compulsions before the age of 18 years (mean = 9.4 years; SD=6.35). 
Subjects disease, schizophrenia, severe mental retardation that does not permit an evaluation 
to characterize the psychiatric disorder, Tourette disorder (TS), or OCD occurring 
exclusively in the context of depression (secondary OCD) were excluded. In addition, 
individuals were removed from the sample if they were previously diagnosed with brain 
pathology including brain tumors, Huntington’s Disease, Parkinson’s Disease, or 
Alzheimer’s Disease. Each case was evaluated by a PhD-level clinical psychologist using 
the Structured Clinical Interview for DSM-IV (SCID) modified and extended to include 
additional symptom and diagnostic information as indicated in the supplementary material. 
Final diagnostic status was assigned based on the consensus of two psychiatrists or 
psychologists reviewing the case independently. Both parents of the proband were also 
recruited whenever possible. When parents were unavailable for participation, unaffected 
siblings were recruited. Genotyping was performed at the Johns Hopkins SNP Center using 
Illumina’s HumanOmniExpress bead chips (Illumina Inc., San Diego, CA, USA). More 
details on the diagnostic assessment and the genotyping process are provided in the 
supplementary materials and methods.
To increase the power of the study to detect significant association, we also included 1 984 
unrelated controls (genotyped with Illumina’s HumanOMNI1-QUAD bead chip) from a 
previously published study on Parkinson’s disease (dbGaP accession number 
phs000196.v2.p1) 24, 25. Individuals with a self-reported or diagnosed neuropsychiatric 
disorder at the time of enrollment were excluded from the present study.
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Quality control of genotyping data
We followed a stringent quality control (QC) protocol that was designed to minimize 
occurrence of false positive signals, which included checking the relatedness of samples (i.e. 
verifying the relationship reported from the participating clinical centers) and reported sex 
(based on deviations from expected heterozygosity rates based on x-chromosomal markers 
in the analysis; PLINK standard parameters were used). In addition, evidence for genotyping 
errors at the sample / marker level was evaluated by searching for an excess of “Mendelian 
inconsistencies” in the data (as indicated by substantial deviation from the empirical 
distributions in both measurements). Multidimensional scaling (MDS) analyses were 
performed on singleton OCD cases and unselected controls, as implemented into Plink 26. 
Samples were removed when they significantly deviated in the first two MDS dimensions (> 
4 standard deviation from the mean). Although inherently robust against population 
stratification, substantial heterogeneity in the population-based study cohorts would have 
lead to decreased power for our analytical approach (see below). More details on the QC 
process are provided in the supplementary materials and methods section. Use of the 
described filters resulted in a final analysis dataset comprising 5 061 individuals from the 
OCGAS samples and additional controls, with available genotypes for 549 123 autosomal 
markers.
Statistical analyses
For the single-marker association analyses, we used a recently published method for 
combining family-based and population-based data. More precisely, family-based 
association testing of within-family information is combined with population-based analyses 
of between-family information and the association analyses of unrelated study subjects 27. 
This hybrid approach is inherently robust to population stratification and potentially 
increases statistical power compared to a classic meta-analysis design 27. As part of our 
analytical pipeline we therefore computed P-values for all autosomal markers and both the 
within and the between family information using PBAT 28. The two P-values were 
subsequently combined using a weighted Z-score statistic as implemented via METAL 29.
Gene-based statistics were derived as fixed Z scores, as implemented in FORGE 30. More 
information on the approach is provided elsewhere 31. Here we used the single-marker 
results of our combined OCGAS GWAS. Information about the correlation pattern in the 
data was provided through usage of HapMap phase 2 samples 32. A maximum of 1 000 000 
permutations were used per gene (adaptive approach) and analyses included an additional +/
− 20kb sequence information based on positions obtained from ENSEMBL v70 33. We used 
the gene-based results in two ways: First we used them to agnostically search for genes that 
are associated with OCD. Second, we used them to follow-up on gene-set based results from 
the IOCDF-GC study, which reported an enrichment of association signals for two gene sets 
that comprised high confidence targets of two miRNA families 21. In addition, we used 
information from a global interactome for Homo sapiens in order to identify high confidence 
interactors of DLGAP1 and GRIK2 (confidence threshold > 0.95) 34. No sub-network 
reduction was applied and only genes representing first neighbors of DLGAP1 and/or 
GRIK2 in the global interactome were considered for this analysis. We used gene-based 
results in order to identify an enrichment of association with OCD in interaction partners of 
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DLGAP1 and the ionotropic kainate 2 glutamate receptor (GRIK2). This analysis was 
motivated by the assumption that biologically closely related genes of these previously 
described OCD risk genes would make reasonable candidates for hypothesis driven 
downstream analyses. Based on an assumed similarity between these genes with regards to 
an involvement in common biological processes and provided that, on a broader level, these 
biological processes themselves are associated with the phenotype under study it seems 
reasonable to hypothesize that focusing on biologically closely related genes (see above) 
helps to identify new disease genes (through reduction of some of the multiple testing 
burden in standard GWAS). More information on the usage of the interactome data and the 
visualization of the resulting networks are found in the supplementary material and methods. 
In brief, we would like to emphasize that our analyses represent a simple, hypothesis driven 
approach for inclusion of the human interactome data, rather than an exhaustive network 
science approach (making use among others of topological features of the interactome other 
then the status of direct interaction). While the latter has been successfully used with 
neuropsychiatric traits in the past, we felt that this evolving field still needs some further 
improvements and therefore decided to refrain from these kinds of analyses.
Results
Single SNP association
Analysis of the 549 123 autosomal markers revealed a nominally significant result at the 
level of α=0.05 for 27 283 markers. Among these, 456 markers reached a P-value of less 
than 0.001 and 54 markers were identified with a P<0.0001. As expected due to the 
stringent study design, no evidence for population stratification was observed (see also 
Supplementary Figure S1). Figure 1 shows the ‘Manhattan’ plot of the association results 
across the autosomal genome and Table 1 reports the association between single SNPs and 
OCD with P<1×10−5. No marker tested for association met the standard of genome-wide 
significance. The smallest P-value for our study was observed with a marker on 
chromosome 9 (rs4401971) at a P-value of 4.13×10−7. This SNP is 1.28 Mb from the 5′ end 
of the protein tyrosine phosphatase, receptor type, D gene (PTPRD, isoform 1; according to 
RefSeq). The second most significantly associated SNP (rs6876547, P=1.76×10−6) is 
located in a region of cadherin clusters and it is of note, that a second, independent SNP 
(rs6452234, P=1.13×10−5, r2<0.2, distance ~650kb) is located in the same region. The 
nearest flanking protein coding genes are the cadherin 9, type 2 (CDH9, 1 308 kb) and the 
cadherin 10, type 2 (CDH10, 927 kb) genes. A ‘regional association plot’ of these two top 
regions is provided in Figure 2.
We used the single-maker association signals to follow up the results from the recent 
IOCDF-GC GWAS 21. For the markers listed in Table 1 of that study, we found evidence 
for association with a marker (rs2205748, same effect allele and direction of effect) on 
chromosome 6 near the genes GRIK2 (distance to gene 1.94 Mb) and the HECT domain and 
ankyrin repeat containing E3 ubiquitin protein ligase 1 gene (HACE1, 713 kb) with an 
uncorrected P-value of 0.0493 in our study (P=8.52×10−6 in the original IOCDF-GC trio-
case-control analysis). One additional region (harboring the gene for the cAMP-specific 
phosphodiesterase 4D, PDE4D) showed a nominal significant signal; however, the effect 
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(based on the same effect allele) was in the opposite direction (compared with the IOCDF-
GC finding). Though no other marker among the tested SNPs from the IOCDF-GC GWAS 
reached a significant result, it is of note that, for the region around DLGAP1 an independent 
SNP in our analyses (rs3866988) yielded a P-value of 2.67×10−4 and thus indicating this 
region as a susceptibility factor for OCD (r2=0.023, D′=0.316 between rs3866988 and 
rs11081062/ rs11663827, based on 1 000 genomes data). It is also of note, that 12 out of 15 
markers (counting the DLGAP1 markers in perfect LD only once) show the same direction 
of effects for the effect alleles in both the IOCDF-GC and OCGAS analyses (binominal test 
with probability 0.5 = sign test: P=0.0176). Detailed results for the follow-up of the IOCDF-
GC results are found in Table 2.
Gene-based findings
Gene-based analyses for 21 567 genes (protein-coding genes and miRNAs) resulted in an 
experiment-wise significant result for two genes, the IQ motif containing K gene (IQCK) 
and the chromosome 16 open reading frame 88 gene (C16orf88; Pcorr<0.0215; P<1×10−6). 
Both genes are located in the same chromosomal region (16p12.3) and share their leading 
SNP, i.e. the SNP with the lowest P-value that is annotated to the gene (rs1544352; 
P=1.94×10−5). The only other gene that shows a P-value < 1×10−4 is the orofacial cleft 
candidate1 gene (OFCC1; P=6.29×10−5). A more detailed list of association results for the 
gene-based analyzes are given in Table 3 and a ‘regional association plot’ for the OFCC1 
locus is provided in Figure 2.
Query of the interactome 34 for high confidence interactors of DLGAP1 and GRIK2 
identified 169 interactors of DLGAP1 and 161 interactors for GRIK2 (246 interactors for 
both of them together). Gene-based analyses revealed that 21 (out of 246) genes showed a 
nominal significant P-value (one-sided P=0.075). This included 16 genes for DLGAP1 (one-
sided P=0.069) and 14 genes for GRIK2 (one-sided P=0.135). It is of note that GRIK2 itself 
was identified as interactor of DLGAP1 and showed a nominal significant gene-based P-
value of 0.03. Among the list of other nominal significant genes are the neuronal 
differentiation 6 gene (NEUROD6, P=0.010), the synaptic vesicle glycoprotein 2A gene 
(SV2A, P=0.026), the ionotropic, AMPA 4 glutamate receptor gene (GRIA4, P=0.039), and 
the solute carrier family 1 (glial high affinity glutamate transporter), member 2 gene 
(SLC1A2, P=0.035). A full list of these results is given in Supplementary Table S4.
We also attempted to replicate a reported enrichment of association signals for two gene sets 
that comprised high confidence targets of two miRNA families (see the Stewart et al OCD 
GWAS). Analyses of the miRNA families of predicted miR-130ac/301ab/301b/301b-3p/
454/721/4295/3666 (miRNA set 1) and miRNA-219-5p/508/508-3p/4782-3p (miRNA set 2) 
targets showed nominal significance for 3 out of 45 high confidence targets in miRNA set 1 
and 14 out of 145 high confidence targets in miRNA set 2. The number of nominal 
significant genes for both sets are higher then expected by chance; however, for both sets, no 
significant enrichment for OCD associated genes was found in either set (one-sided P=0.323 
and one-sided P=0.087, respectively). It is of note that one of the high confident targets in 
miRNA set 2 (the epiregulin gene, EREG) did demonstrate an experiment-wise significance 
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level (correcting for the number of tests performed in miRNA set2; P=3.06×10−4; 
Pcorr=0.044).
Discussion
Here we report the results of a GWAS including a sample of 1 406 patients with OCD, that 
was predominantly family-based, but which also included a case-control subsample to 
increase power (resulting in a total sample of 5 061 individuals). The study identified 
interesting candidate genes for OCD, but failed to detect any genome-wide significant 
findings. This is similar to what has been observed for other psychiatric phenotypes such as 
schizophrenia, for which genome-wide significant findings were only achieved after either 
starting with more samples in the discovery step 35, 36 or making use of large follow-up 
samples, that were orders of magnitude larger then the original discovery samples 37, 38. We 
suspect that, with additional samples, the findings of genetic studies for OCD will be more 
robust, and our currently suggestive findings may reach genome-wide significance.
Of particular interest is the signal near the PTPRD gene (rs4401971), the most significant 
found in this study (P=4.13×10−7). PTPRD is a member of the receptor protein tyrosine 
phosphatase family, which comprises transmembrane signaling molecules that regulate a 
variety of cellular processes including cell growth and differentiation 39. Pre-synaptic 
PTPRD promotes the differentiation of glutamatergic synapses 40–43 and interacts with Slit 
and NTRK-like family member 3 (SLITRK3) which acts as a postsynaptic adhesion 
molecule. Together both proteins selectively regulate inhibitory GABAergic synapse 
development 44. This is interesting because molecules in the same family, SLITRK5 and 
SLITRK1, have been shown to be associated with TS and OCD, the former in a mouse 
model and the latter in a TS genetic study 45, 46.
Mice deficient in PTPRD show impairment in learning and memory tasks, especially spatial 
learning, and exhibit enhanced long-term potentiation (LTP), a form of activity dependent 
plasticity 47. This is relevant to OCD, in that memory deficits have been reported for this 
condition 48. PTPRD also has been shown to be associated with restless leg syndrome 
(RLS) 49 and hemizygous deletions were detected in four unrelated attention deficit 
hyperactivity disorder (ADHD) probands 50.
Our second strongest association finding is located in a region of cadherin clusters. It is 
known that CDH9 has been reported associated with OCD 51. Furthermore, six SNPs 
between cadherin 10 (CDH10) and cadherin 9 (CDH9) were significantly (as well as in a 
replication sample) associated with autism spectrum disorders (ASD) 52 and was a top 
(although not significant) association signal in anorexia nervosa 53.
Analysis of previously identified GWAS hit regions for the IOCDF-GC study 21 revealed 
that 12 out of the 15 strongest signals in that study showed associations with the same 
direction of effects (based on the same effect alleles) in both the IOCDF-GC and OCGAS 
analyses (sign test P=0.0176). This observation supports the hypothesis that future 
collaborative studies (meta- and mega-analyses) will be able to identify OCD genes at the 
level of genome-wide significance. Support for association with OCD was particularly 
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found in two previously identified genetic regions (see above). The most interesting region 
harbors the DLGAP1 gene. In the IOCDF-GC study signals in this gene were the top signals 
from the case-control analysis. Although the specific SNP from the former study was not 
found significant in this study, there was a prominent signal for an independent nearby 
marker (P=2.67×10−4). This observation potentially serves as independent evidence for 
association of markers in this region. DLGAP1 is a member of the neuronal postsynaptic 
density complex and is in the same family as the DLGAP3 gene, which has been shown in a 
convincing way to be responsible for OCD-like behaviors in DLGAP3 knockout mice 
models 54. A marker in the second genetic region (harboring GRIK2), also a top signal in the 
IOCDF-GC GWAS showed nominal significance in our study (P=0.045). Although failing 
to reach experiment-wise significance it is of note that DLGAP1 and GRIK2 interact 
(FUNCOUP 34). Following up these signals in a gene-set analysis for high confidence 
interaction partners of DLGAP1 and GRIK2 (identified using FUNCOUP 34) showed a trend 
for association and pointed to a potential role of a set of DLGAP1 and GRIK2 interactors in 
the etiology of OCD, involving genes such as NEUROD6, SV2A, GRIA4, and SLC1A2. 
Interestingly PTPRD was part of this gene set. It is of note that for both DLGAP1 and 
GRIK2 we identified more then 160 interactors each, thus indicating they are highly 
connected nodes (hubs) in the interactome. Earlier findings have suggested that only genes 
that are essential in (early) development (“essential genes”) tend to encode hub proteins, 
while the vast majority of disease genes are nonessential and show no tendency to encode 
hub proteins 55. This might point to DLGAP1 and GRIK2 as being essential genes in early 
(neuro-)development. However, more studies are warranted to confirm this hypothesis.
Gene-based association analyses identify significant signals in two genes, IQCK and 
C16orf88; however, this finding is not amenable to interpretation at this time. The next 
strongest gene-based signal in OFCC1 is intriguing because a variant within the exon of this 
gene has been reported in seven affected individuals of family segregating OCD, TS, and 
ADHD 56.
This study employed careful and comprehensive phenotyping; MD and PhD-trained 
psychologists conducted all assessments and recruitment sites used the same assessment 
approach and all cases were reviewed at a single site (JHU) to ensure diagnostic 
replicability. Given the likely etiologic heterogeneity of OCD, the comprehensive 
phenotyping provides opportunities for future studies (through subtyping based e.g. on 
factor-analytical approaches).
A limitation of this study is that the power to detect significant association signals for small 
effect sizes is limited by the sample size. This has been clearly demonstrated in many 
GWAS efforts for other neuropsychiatric conditions (e.g., schizophrenia) in which studies of 
comparable size have failed to identify significant association signals. Yet, when sample 
sizes have increased (in some case 10 or more fold), then multiple significant signals were 
identified. Power was improved in this study by using a hybrid analytic approach that 
included both family and case-control samples in the analysis. In conclusion, while this 
OCD GWAS study did not identify a study-wide significant association finding, several of 
the strongest findings are particularly interesting. There are both plausible biologic 
hypotheses and prior genetic evidence, for either OCD or related conditions, for the two 
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most significant association findings, PTPRD and CDH9/CDH10. The finding that the 
signals in this GWAS concur with respect to allele and direction significantly with the top 
signals in a second reported OCD GWAS, suggests that similar genetic underpinnings of 
OCD are identified in both studies. Moreover, while not a replication in the full sense, 
findings for the genes DLGAP1 and GRIK2 suggest that they are both relevant candidates 
genes for OCD. The suggestive findings in this study await replication in larger samples.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Manhattan plot for OCGAS GWAS
Shown are the result for the hybrid analysis of the within and between family component of 
the OCGAS GWAS. A thin blue line indicates level of suggestive evidence for association 
(1 × 10−5) and a thin red line indicates genome-wide significance (5 × 10−8).
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Figure 2. Regional association plots for top regions in OCGAS GWAS
The most associated marker in the region (see table 2 and S2, purple dot) is centered in a 
genomic window of 5 Mb (hg19). P-values for the OCGAS GWAS are given. The linkage 
disequilibrium (LD) strength (r2; data from the 1000 genomes project European samples) 
between the sentinel single nucleotide polymorphism and its flanking markers is 
demonstrated by the coloring of the dots for the neighboring markers (ranging from red = 
high to blue = low). The recombination rate (cM/Mb; second y axis) is plotted in blue. Plots 
are given for the a) chromosome 9 region harboring PTPRD (clump 1 in table 2), b) the 
chromosome 5 region (clump 2 in table 2), and c) the chromosome 16 region harboring the 
two genes that were identified in the gene-based analysis, IQCK and C16orf88.
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